<DOC>
	<DOCNO>NCT02543268</DOCNO>
	<brief_summary>The purpose study compare humoral immune response induce 3 different batch Ad26.ZEBOV measure enzyme - link immunosorbent assay ( ELISA ) Ebola virus ( EBOV ) GP ( Glycoprotein ) 56 day post prime .</brief_summary>
	<brief_title>A Study Evaluate Immunogenicity , Safety Tolerability Ad26.ZEBOV MVA‐BN‐Filo Healthy Adult Participants</brief_title>
	<detailed_description>This randomize , double - blind , placebo - control , parallel - group , multicenter , Phase 3 study evaluate immunogenic equivalence heterologous prime - boost regimen use 3 different batch Ad26.ZEBOV healthy adult participant . The study consist screen period 6 week , vaccination period participant vaccinate baseline ( Day 1 ) , follow boost vaccination Day 57 , post-vaccination phase 6 month post‐boost visit ( Day 237 ) . The participant randomize baseline ( Day 1 ) 2:2:2:1 ratio Groups 1 , 2 , 3 4 . Safety monitor throughout study .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy Investigator 's clinical judgment basis medical history , physical examination , electrocardiogram ( ECG ) vital sign perform Screening Healthy basis clinical laboratory test perform Screening Before randomization , woman must either childbearing potential practicing ( intend practice ) highly effective method birth control consistent local regulation regard use birth control method participant participate clinical study , begin least 28 day prior vaccination OR childbearing potential : postmenopausal ( great [ &gt; ] 45 year age amenorrhea least 2 year age amenorrhea least 6 month , serum follicle stimulate hormone ( FSH ) level &gt; 40 international unit per milliliter [ IU/L ] ) ; permanently sterilize ( example , bilateral tubal occlusion [ include tubal ligation procedure consistent local regulation ] , hysterectomy , bilateral salpingectomy , bilateral oophorectomy ) ; otherwise incapable pregnancy Woman childbearing potential must negative serum [ beta‐human chorionic gonadotropin ( beta‐hCG ) ] Screening negative urine beta‐hCG pregnancy test immediately prior study vaccine administration Man sexually active woman childbearing potential vasectomy perform 1 year prior Screening must willing use condom sexual intercourse begin prior enrollment , addition document birth control method use female partner Having receive candidate Ebola vaccine Diagnosed Ebola virus disease , prior exposure Ebola virus , include travel West Africa le 1 month prior Screening . West Africa include limited country Guinea , Liberia , Mali , Sierra Leone Having receive experimental candidate adenovirus serotype 26 ( vector : Ad26 ) Modified Vaccinia Ankara ( MVA ) base vaccine past Known allergy history anaphylaxis serious adverse reaction vaccine vaccine product ( include constituent study vaccine ) include know allergy egg , egg product aminoglycosides Presence acute illness temperature great equal ( &gt; = ) 38.0 centigrade ( °C ) Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Ebola virus</keyword>
	<keyword>Ebola virus disease ( EVD )</keyword>
	<keyword>Filoviruses</keyword>
	<keyword>Monovalent vaccine</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Human adenovirus serotype 26 ( Ad26 ) express Ebola virus Mayinga variant glycoprotein ( Ad26.ZEBOV )</keyword>
	<keyword>Modified Vaccinia Virus Ankara ‐ Bavarian Nordic Filo‐vector ( MVA‐BN Filo )</keyword>
	<keyword>Healthy participant</keyword>
</DOC>